Exclusive Coverage of the European Society for Medical Oncology Congress 2022
Coverage of the European Society for Medical Oncology Congress 2022, which took place in a virtual format and in person in Paris, France.
Uncovering the Economic Burden of Chronic Cough and the Promising Role of Emerging Targeted Therapies
Volume: 28
Issue: 9
Emerging Care Management Strategies for Severe Asthma: Integrating Biologic Therapy
Issue: 11
The Impact of PCSK9 Modulation on Cardiovascular Outcomes: Recent Advances and the Managed Care Implications
Issue: 8
A Population Health Approach to Managing Heart Failure
Advancing Alzheimer Disease Treatment: Updates and Insights for Managed Care Professionals
Issue: 10
Best Practices and Future Opportunities in Care Delivery for Severe, Uncontrolled Asthma: an AJMC® Profiles in Care
Variations in Managing Chronic Kidney Disease Associated With Type 2 Diabetes Across the United States and Validation of the FINE-CKD Model for Future Health Technology Assessments of Finerenone
Issue: 6
VIVJOA™ (OTESECONAZOLE) CLINICAL MONOGRAPH
The Clinical and Economic Benefits Associated With Novel Multi-Cancer Early Detection Tests: Conference Highlights from the 2022 ISPOR Annual Meeting
Issue: 7
Updates and Evolving Treatment Strategies in Acute Myeloid Leukemia
Issue: 1 Suppl
Improving HER2 Biomarker Testing in Metastatic Colorectal Cancer
The Evolving Landscape of Demodex Blepharitis Management
Disease Burden of Relapsing-Remitting Multiple Sclerosis
Oncology Care Pathways Supporting the Use of High-value Treatments for NSCLC
Uptake of Oncology Biosimilars: Managed Care Strategies to Improve Value-Based Care Systems
Issue: 5
Analyzing the Value of Continuous Glucose Monitoring in Diabetes Care and Overcoming Barriers Through Expanded Pharmacy Access
Issue: 4
Implementing the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: SGLT2 Inhibitors, Treatment Sequencing, and Value Statements
The Role of Real-World Evidence, Patient-Reported Outcomes, and Economic Models in Oncology Formulary Decisions and the Role of Real-World Evidence in Oncology Product Registration
Management of Interstitial Lung Disease: Emerging Therapies and Unmet Needs
Role of Real-World Evidence in the Evolving Treatment Landscape of Multiple Myeloma
ZEPOSIA® (ozanimod), a Sphingosine 1-Phosphate Receptor Modulator for Relapsing Forms of Multiple Sclerosis
Clinical Trial Data Can Be Supplemented by Real-World Evidence: An Example for an Oral Anticoagulant in Patients With Nonvalvular Atrial Fibrillation at Risk of Stroke
Real-World Evidence Associated With a First-Generation BTK Inhibitor in Patients With CLL/SLL
A Personalized Approach to Disease Management in Psoriasis
Advancing the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema With Novel and Emerging Monoclonal Antibody Therapy
Issue: 3
From Evidence to Implementation: Clarifications Around the US Preventive Services Task Force Recommendations for HIV Pre-Exposure Prophylaxis
Current Landscape of Treatment Options for Patients With Amyotrophic Lateral Sclerosis (ALS)
A Review of a Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes
Optimizing Outcomes in Multiple Sclerosis Through Individualized Treatment: Managed Care Considerations
